SEC Form 4 · accession 0001349193-26-000003
ImmunityBio, Inc. · IBRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Wesley Clark
Director
Period of report
Jun 9, 2026
Accepted (ET)
Jun 10, 2026 · 8:11 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001326110
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $7.25 | Jun 9, 2026 | A | 65,600 | A | — | Jun 9, 2036 | Common Stock | 65,600 | 65,600 | D |
Explanation of responses
- F1Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders.
Remarks
Exhibit 24 - Power of Attorney